WILMINGTON, Del., Oct. 17, 2024 /PRNewswire/ — IgniteData, a company focused on healthcare technology solutions, announces a new collaboration with Mayo Clinic to deploy its Archer platform across multiple sites in the U.S., aiming to improve the management of clinical trial data by enhancing the transfer of information from Electronic Health Records (EHR) to Electronic Data Capture (EDC) systems.
IgniteData works with research institutions globally, and this agreement, initially focused on oncology, seeks to increase Clinical Research Coordinator (CRC) efficiency and accelerate clinical trial processes. The automation and streamlining of data transfer through Archer reduces the need for manual data entry, providing quicker and more reliable data for drug development timelines.
“This collaboration highlights our focus on improving clinical trial efficiency,” said Tim Virdee, VP Hospital Partnerships at IgniteData. “By integrating the Archer platform, we aim to support faster and more reliable data transfer between EHR and EDC systems.”
IgniteData’s Archer platform was selected for its compatibility with multiple EHR and EDC systems and its commitment to data security, ensuring no patient data is persisted.
IgniteData
IgniteData is transforming the future of clinical trials through its cloud-based Virtual Research Assistant, Archer. A system-agnostic solution, Archer brings modern interoperability between EHR and key research systems, such as EDC, to provide seamless, secure transfer of clinically-validated data for clinical trials. www.ignitedata.com
SOURCE IgniteData
CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…
Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…
Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…
Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…
Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…